Protagonist Therapeutics PTGX Non Cash Lease Expense
Non Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept ptgx:NonCashLeaseExpense.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's non cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's non cash lease expense?
- Protagonist Therapeutics (PTGX) reported non cash lease expense of $439K in Q1 2026.
- How has Protagonist Therapeutics's non cash lease expense changed year-over-year?
- Protagonist Therapeutics's non cash lease expense decreased by 22.8% year-over-year, from $569K to $439K.
- What is the long-term trend for Protagonist Therapeutics's non cash lease expense?
- Over 2 years (2023 to 2025), Protagonist Therapeutics's non cash lease expense has grown at a -17.5% compound annual growth rate (CAGR), from $2.34M to $1.59M.
- What does non cash lease expense mean?
- This represents the non-cash portion of lease expenses recognized in the income statement, typically related to the amortization of right-of-use assets. It is added back to net income in the cash flow statement to reconcile accounting expenses with actual cash outflows. Monitoring this helps investors understand the impact of lease accounting standards on reported profitability.